Loading...
Please wait, while we are loading the content...
Similar Documents
Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Pulini, Stefano Rupoli, Serena Goteri, Gaia Pimpinelli, Nicola Alterini, Renato Tassetti, Angela Scortechini, Anna Rita Offidani, Massimo Mulattieri, Simonetta Stronati, Andrea Brandozzi, Giuliano Giacchetti, Alfredo Mozzicafreddo, Giorgio Ricotti, Giuseppe Filosa, Giorgio Bettacchi, Alberta Simonacci, Marco Novelli, Nicolino Leoni, Pietro |
| Copyright Year | 2007 |
| Abstract | Pegylated liposomal doxorubicin (Peg-Doxo) is a promising drug for advanced/recalcitrant primary cutaneous T-cell lymphomas (CTCLs). This prospective phase II trial enrolled 19 patients. We observed overall and complete response rates of 84.2% and 42.1% (with no significant differences between stage I-IIA and IIB-IV patients), and 11% grade III/IV toxicity. After a maximum 46 month-follow-up, median overall (OS), event-free (EFS) and progression-free (PFS) survival were 34, 18 and 19 months. OS, EFS and PFS rates at 46 months were 44%, 30% and 37% respectively. Peg-Doxo seems to be an active and safe principle that should be used in plurirelapsed, early stage-MF and in combination with other chemotherapeutic agents in advanced and aggressive CTCLs. |
| File Format | PDF HTM / HTML |
| DOI | 10.3324/haematol.10879 |
| PubMed reference number | 17488695 |
| Journal | Medline |
| Volume Number | 92 |
| Issue Number | 5 |
| Journal | Haematologica |
| Alternate Webpage(s) | http://www.haematologica.org/content/haematol/92/5/686.full.pdf |
| Alternate Webpage(s) | https://doi.org/10.3324/haematol.10879 |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |